Tsubota Laboratory

Tsubota Laboratory is a Japan-based biotechnology company dedicated to the research and development of innovative therapies for ophthalmological conditions, with a primary focus on myopia, dry eye, and presbyopia. Founded by Dr. Kazuo Tsubota, a pioneer in corneal research, the company utilizes a unique 'Violet Light' technology platform designed to stimulate OPN5 receptors to inhibit myopia progression. Their business model is primarily 'fabless,' focusing on intellectual property and R&D while partnering with established pharmaceutical and optical companies for manufacturing and distribution. Tsubota Laboratory's pipeline includes both medical devices, such as specialized myopia-control eyewear, and pharmaceutical candidates for various ocular surface diseases. The company is listed on the Tokyo Stock Exchange and maintains strong academic ties with Keio University.